Expands Alcon’s retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease
Alcon's established presence and
One drop works to significantly reduce redness, with results lasting up to 12 hours1
Lasts up to 50% longer than Lumify1-2,*
Expands Alcon's portfolio of consumer eye care solutions and will be available in
Formulated with hyaluronic acid, Systane® PRO PRESERVATIVE-FREE instantly hydrates dry eyes1
Systane® PRO PF is a multi-dose preservative-free triple action formula that hydrates, restores and protects all types of
Features industry-leading red reflex for stable, consistent visualization and Color Tunable Illumination for improved surgical precision1,2,*,†
Latest addition to the UNITY platform that allows for modular upgrades
Alcon Inc. (SIX/NYSE:ALC), today announced that it has commenced and priced a public offering of EUR 500 million aggregate principal amount of its 3.875% senior notes due 2033 (the "Notes"). The Notes will be
Second-quarter 2026 sales of $2.8 billion, up 8% on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025
Returned $538 million to shareholders through dividends and share repurchases on a
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologiesCollaboration aims to combine best-in-class PCIOL optics with first-in-class platform
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies
Collaboration aims to combine best-in-class PCIOL optics with first-in-class
First-quarter 2026 sales of $2.7 billion, up 10% on a reported basis, or up 6% constant currency1 (cc), versus first-quarter 2025
First-quarter 2026 diluted EPS of $0.39; core diluted EPS2 of $0.85
Dividend of
Shareholders approve all agenda items presented
R. Scott Herren elected as new independent member of the Board
2025 Compensation Report and Report on Non-Financial Matters approved in consultative votes
Alcon
New partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game.
This season, Alcon, the global leader in eye care dedicated
TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2
TruPlus demonstrates higher distance image quality across pupil sizes and
Alcon welcomes its shareholders to its fourth in-person AGM
Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member
Proposed dividend of CHF 0.28 cash per share
Alcon
Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies'
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,*
PanOptix delivers outstanding patient satisfaction and freedom from
